Bipolar Disorder (2018) |
1.89 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Depressed Affect (Nagel 2018) |
1.55 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Intelligence (Savage-Jansen 2018) |
3.03 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
RBL2 RBM6 TCTA |
Schizophrenia vs Biploar Disorder |
1.81 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 RBM6 |
Crohns Disease (2017) |
3.97 |
6 |
2 |
4.4 |
-0.65 |
1.6e-01 |
FNDC4 JAZF1 NOTCH2 PMS2P5 RBM6 TCTA |
Irritable Bowel Disease (IBD) |
2.66 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 PMS2P5 RBM6 |
Ulcerative Colitis (UC) |
1.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Reaction Time |
1.38 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCTA |
Verbal and Numeric Reasoning (VNR) |
3.06 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
RBL2 RBM6 TCTA |
Breast Cancer |
3.97 |
5 |
1 |
2.2 |
-0.60 |
2.8e-01 |
DAND5 NOTCH2 PMS2P5 SNUPN TCF7L2 |
Age at First Birth |
3.20 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
RBM6 TCTA |
Crohns Disease (2012) |
3.09 |
4 |
0 |
0.0 |
-0.99 |
6.2e-03 |
FNDC4 NOTCH2 RBM6 TCTA |
Fasting Glucose |
7.52 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 SMYD2 |
HDL Cholesterol |
1.58 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
LDL Cholesterol |
1.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Schizophrenia (2014) |
1.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
KCNJ11 |
Triglycerides |
20.71 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Type 2 Diabetes (T2D) (2012) |
15.64 |
10 |
5 |
11.1 |
0.98 |
1.0e-06 |
ANK1 EIF2S2P3 IGF2BP2 JAZF1 KCNJ11 SSR1 TCF7L2 UBE2E2 WFS1 ZCCHC24 |
Blood Eosinophil Count |
1.46 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
EIF2S2P3 JAZF1 RBM6 |
Blood Platelet Count |
3.63 |
7 |
4 |
8.9 |
-0.57 |
1.8e-01 |
EIF2S2P3 FNDC4 IGF2BP2 KCNJ11 SNUPN UBE2E2 ZCCHC24 |
Blood Red Count |
3.75 |
7 |
3 |
6.7 |
0.88 |
8.9e-03 |
DAND5 EIF2S2P3 FNDC4 IGF2BP2 RBM6 SNUPN TCTA |
Blood White Count |
2.85 |
4 |
3 |
6.7 |
-0.91 |
9.0e-02 |
FNDC4 RBM6 SNUPN ZCCHC24 |
Heel T-Score |
2.45 |
7 |
4 |
8.9 |
0.53 |
2.2e-01 |
IGF2BP2 JAZF1 PMS2P5 RBM6 SMYD2 SSR1 TCTA |
BMI |
3.66 |
9 |
7 |
15.6 |
0.18 |
6.4e-01 |
DAND5 FNDC4 JAZF1 KCNJ11 PMS2P5 RBM6 TCF7L2 TCTA ZCCHC24 |
Height |
3.45 |
8 |
7 |
15.6 |
0.23 |
5.9e-01 |
DAND5 FNDC4 JAZF1 KCNJ11 RBL2 SNUPN SSR1 UBE2E2 |
Waist Hip Ratio (WHR) |
4.77 |
9 |
7 |
15.6 |
0.98 |
5.3e-06 |
EIF2S2P3 IGF2BP2 JAZF1 KCNJ11 RBL2 SNUPN TCF7L2 TCTA ZCCHC24 |
Systolic Blood Pressure |
2.68 |
6 |
3 |
6.7 |
0.67 |
1.4e-01 |
FNDC4 JAZF1 KCNJ11 PMS2P5 TCF7L2 TCTA |
Smoking Status |
1.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
KCNJ11 |
Allergy or Eczema |
1.56 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 JAZF1 |
Cardiovascular Disease |
3.20 |
5 |
3 |
6.7 |
0.50 |
3.9e-01 |
FNDC4 IGF2BP2 KCNJ11 PMS2P5 TCTA |
Hypothyroidism (self reported) |
1.12 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 |
Respiratory disease |
1.97 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 JAZF1 RBM6 |
Type 2 Diabetes (T2D) (2018) |
32.52 |
19 |
18 |
40.0 |
0.99 |
3.3e-18 |
ANK1 DAND5 EIF2S2P3 FNDC4 IGF2BP2 JAZF1 KCNJ11 NOTCH2 PMS2P5 RBL2 RBM6 SMYD2 SNUPN SSR1 TCF7L2 TCTA UBE2E2 WFS1 ZCCHC24 |
Lung FEV1/FVC ratio |
0.80 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
IGF2BP2 |
Lung FVC |
2.39 |
6 |
3 |
6.7 |
-0.78 |
6.9e-02 |
FNDC4 IGF2BP2 JAZF1 SNUPN SSR1 ZCCHC24 |
Neuroticism |
0.93 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Hair Pigment |
0.63 |
4 |
2 |
4.4 |
-0.06 |
9.4e-01 |
FNDC4 JAZF1 SSR1 ZCCHC24 |
Tanning |
0.71 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
FNDC4 JAZF1 NOTCH2 |
Number of treatments/medications taken |
4.03 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 PMS2P5 RBM6 |
Relative age of first facial hair |
2.06 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 PMS2P5 |
Other serious medical condition/disability diagnosed by doctor |
1.48 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PMS2P5 |
Systolic blood pressure, automated reading |
1.82 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
KCNJ11 PMS2P5 TCTA |
Eye problems/disorders: Diabetes related eye disease |
6.01 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 TCF7L2 WFS1 |
Medication: Co-codamol |
1.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Medication: Metformin |
21.84 |
17 |
8 |
17.8 |
0.99 |
2.0e-15 |
ANK1 DAND5 EIF2S2P3 FNDC4 IGF2BP2 JAZF1 KCNJ11 PMS2P5 RBL2 RBM6 SNUPN SSR1 TCF7L2 TCTA UBE2E2 WFS1 ZCCHC24 |
Diabetes (father) |
15.18 |
8 |
3 |
6.7 |
0.99 |
1.4e-07 |
ANK1 EIF2S2P3 FNDC4 IGF2BP2 JAZF1 SSR1 TCF7L2 WFS1 |
Diabetes (mother) |
13.44 |
8 |
4 |
8.9 |
0.99 |
4.3e-07 |
ANK1 DAND5 EIF2S2P3 FNDC4 IGF2BP2 TCF7L2 UBE2E2 WFS1 |
Pack years adult smoking proportion |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PMS2P5 |
Impedance of leg (right) |
3.63 |
6 |
5 |
11.1 |
-0.16 |
7.6e-01 |
FNDC4 JAZF1 KCNJ11 PMS2P5 RBL2 RBM6 |
Leg fat-free mass (left) |
3.24 |
5 |
3 |
6.7 |
0.39 |
5.1e-01 |
FNDC4 RBL2 RBM6 SNUPN TCTA |
Trunk fat percentage |
2.06 |
4 |
1 |
2.2 |
0.92 |
8.2e-02 |
PMS2P5 RBM6 TCTA ZCCHC24 |
Hand grip strength (right) |
1.36 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 SNUPN |
Fed-up feelings |
1.67 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Relative age voice broke |
2.02 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
PMS2P5 TCTA |
Taking other prescription medications |
3.58 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PMS2P5 RBM6 |
Age when periods started (menarche) |
1.98 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
DAND5 PMS2P5 |
Heel bone mineral density (BMD) T-score, automated (left) |
2.90 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
PMS2P5 RBM6 TCTA |
High blood pressure |
2.51 |
4 |
1 |
2.2 |
1.00 |
2.5e-03 |
KCNJ11 PMS2P5 RBL2 TCTA |
Hayfever, allergic rhinitis or eczema |
1.64 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 JAZF1 |
Sitting height |
2.68 |
7 |
5 |
11.1 |
0.00 |
9.9e-01 |
FNDC4 JAZF1 RBL2 SNUPN SSR1 UBE2E2 ZCCHC24 |
Body mass index (BMI) |
4.07 |
7 |
4 |
8.9 |
0.09 |
8.5e-01 |
FNDC4 JAZF1 KCNJ11 PMS2P5 RBM6 TCF7L2 TCTA |
Impedance of leg (left) |
3.68 |
7 |
4 |
8.9 |
0.06 |
9.0e-01 |
FNDC4 JAZF1 KCNJ11 NOTCH2 PMS2P5 RBL2 RBM6 |
Leg predicted mass (left) |
3.23 |
4 |
3 |
6.7 |
0.36 |
6.4e-01 |
FNDC4 RBL2 RBM6 SNUPN |
Trunk fat mass |
2.47 |
5 |
2 |
4.4 |
0.38 |
5.3e-01 |
JAZF1 PMS2P5 RBM6 TCF7L2 TCTA |
Waist circumference |
3.40 |
6 |
3 |
6.7 |
0.45 |
3.7e-01 |
FNDC4 PMS2P5 RBM6 TCF7L2 TCTA ZCCHC24 |
Past tobacco smoking |
1.52 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DAND5 |
Frequency of tenseness / restlessness in last 2 weeks |
1.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Forced vital capacity (FVC) |
1.93 |
4 |
1 |
2.2 |
-0.51 |
4.9e-01 |
SMYD2 SNUPN SSR1 ZCCHC24 |
Heel bone mineral density (BMD) T-score, automated (right) |
2.43 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
RBM6 TCTA |
Qualifications: None of the above |
2.02 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBL2 RBM6 |
Mouth/teeth dental problems |
1.59 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PMS2P5 |
Allergy |
1.71 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
JAZF1 |
Medication: Simvastatin |
3.93 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 TCF7L2 |
Fluid intelligence score |
3.45 |
4 |
1 |
2.2 |
-0.66 |
3.4e-01 |
KCNJ11 RBL2 RBM6 TCTA |
Illnesses of siblings |
2.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 |
Neuroticism score |
0.96 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Weight |
3.35 |
6 |
3 |
6.7 |
0.31 |
5.5e-01 |
FNDC4 PMS2P5 RBL2 RBM6 TCF7L2 TCTA |
Impedance of arm (right) |
4.23 |
7 |
4 |
8.9 |
-0.09 |
8.5e-01 |
DAND5 FNDC4 JAZF1 KCNJ11 RBM6 TCF7L2 TCTA |
Arm fat percentage (right) |
2.37 |
4 |
1 |
2.2 |
0.16 |
8.4e-01 |
PMS2P5 RBM6 TCF7L2 TCTA |
Trunk fat-free mass |
3.82 |
6 |
5 |
11.1 |
0.47 |
3.5e-01 |
FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 |
Hip circumference |
2.67 |
5 |
3 |
6.7 |
-0.13 |
8.3e-01 |
FNDC4 PMS2P5 RBL2 RBM6 TCF7L2 |
Alcohol intake versus 10 years previously |
3.72 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
FNDC4 RBM6 |
Worrier / anxious feelings |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF7L2 |
Frequency of tiredness / lethargy in last 2 weeks |
1.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SNUPN |
Number of live births |
1.61 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Forced expiratory volume in 1-second (FEV1) |
1.88 |
4 |
0 |
0.0 |
-0.97 |
2.6e-02 |
IGF2BP2 SMYD2 SNUPN ZCCHC24 |
Pulse rate |
3.87 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
FNDC4 RBL2 TCTA |
Qualifications: A levels/AS levels or equivalent |
2.92 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBM6 TCTA |
Mouth/teeth dental problems: Dentures |
2.52 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 PMS2P5 RBM6 |
Asthma |
1.88 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 JAZF1 RBM6 |
Medication: Cholesterol lowering |
5.06 |
4 |
1 |
2.2 |
0.25 |
7.5e-01 |
FNDC4 IGF2BP2 TCF7L2 TCTA |
Prospective memory result |
1.65 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Illnesses of mother |
3.22 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 TCTA |
Forced expiratory volume in 1-second (FEV1), Best measure |
1.90 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 SNUPN ZCCHC24 |
Impedance of arm (left) |
4.37 |
7 |
4 |
8.9 |
-0.08 |
8.6e-01 |
DAND5 FNDC4 JAZF1 KCNJ11 RBM6 TCF7L2 TCTA |
Arm fat mass (right) |
2.96 |
5 |
2 |
4.4 |
0.34 |
5.7e-01 |
FNDC4 PMS2P5 RBM6 TCF7L2 TCTA |
Trunk predicted mass |
3.82 |
6 |
5 |
11.1 |
0.47 |
3.4e-01 |
FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 |
Standing height |
3.35 |
7 |
6 |
13.3 |
0.25 |
5.8e-01 |
DAND5 FNDC4 JAZF1 KCNJ11 RBL2 SNUPN SSR1 |
Breastfed as a baby |
1.61 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 TCTA |
Hair/balding pattern: Pattern 4 |
1.48 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NOTCH2 |
Birth weight of first child |
2.74 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBL2 SSR1 |
Peak expiratory flow (PEF) |
1.67 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 SNUPN |
Ever highly irritable/argumentative for 2 days |
2.36 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 SNUPN |
Mouth/teeth dental problems: Bleeding gums |
1.83 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
WFS1 |
Medication for cholesterol, blood pressure or diabetes |
3.62 |
4 |
0 |
0.0 |
-0.53 |
4.7e-01 |
FNDC4 IGF2BP2 RBM6 TCTA |
Gout (self-reported) |
5.54 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Hypothyroidism/myxoedema (self-reported) |
1.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 |
Medication: Ventolin 100micrograms inhaler |
1.82 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Birth weight |
4.39 |
4 |
2 |
4.4 |
0.06 |
9.3e-01 |
ANK1 EIF2S2P3 SMYD2 SSR1 |
Chronic bronchitis/emphysema (mother) |
1.40 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
High blood pressure (siblings) |
1.89 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Forced vital capacity (FVC), Best measure |
1.96 |
5 |
2 |
4.4 |
-0.14 |
8.2e-01 |
JAZF1 SMYD2 SNUPN SSR1 ZCCHC24 |
Body fat percentage |
2.63 |
6 |
2 |
4.4 |
0.23 |
6.6e-01 |
PMS2P5 RBM6 SNUPN TCF7L2 TCTA ZCCHC24 |
Leg fat percentage (right) |
3.78 |
7 |
3 |
6.7 |
0.36 |
4.3e-01 |
PMS2P5 RBL2 RBM6 SNUPN TCF7L2 TCTA ZCCHC24 |
Arm fat-free mass (right) |
4.12 |
7 |
3 |
6.7 |
0.56 |
1.9e-01 |
FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA |
Comparative body size at age 10 |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Wheeze or whistling in the chest in last year |
3.07 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBM6 |
Age at first live birth |
2.99 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBM6 TCTA |
Health satisfaction |
1.92 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Qualifications: College or University degree |
2.51 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBL2 RBM6 |
Medication: Blood pressure |
2.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PMS2P5 |
Medication: Allopurinol |
5.24 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Medication: Seretide 50 evohaler |
1.82 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Mean time to correctly identify matches |
1.62 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 TCTA |
Whole body fat mass |
2.91 |
4 |
2 |
4.4 |
0.21 |
7.9e-01 |
PMS2P5 RBM6 TCF7L2 TCTA |
Leg fat mass (right) |
3.66 |
6 |
3 |
6.7 |
0.35 |
5.0e-01 |
FNDC4 PMS2P5 RBM6 TCF7L2 TCTA ZCCHC24 |
Arm predicted mass (right) |
4.04 |
7 |
2 |
4.4 |
0.56 |
1.9e-01 |
FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA |
Pulse rate, automated reading |
6.76 |
7 |
5 |
11.1 |
0.50 |
2.6e-01 |
EIF2S2P3 FNDC4 JAZF1 RBL2 RBM6 TCTA WFS1 |
Alcohol intake frequency. |
7.20 |
4 |
4 |
8.9 |
0.15 |
8.5e-01 |
FNDC4 PMS2P5 RBM6 TCTA |
Comparative height size at age 10 |
3.34 |
7 |
4 |
8.9 |
0.34 |
4.6e-01 |
EIF2S2P3 FNDC4 JAZF1 KCNJ11 RBL2 SNUPN UBE2E2 |
Overall health rating |
3.80 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
PMS2P5 RBL2 RBM6 |
Age at last live birth |
3.68 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
EIF2S2P3 RBM6 |
Leg pain on walking |
1.68 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Qualifications: NVQ or HND or HNC or equivalent |
2.44 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Medication: Aspirin |
2.61 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 |
Knee pain experienced in last month |
1.97 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 ZCCHC24 |
Hypertension (Self-reported) |
2.47 |
4 |
1 |
2.2 |
1.00 |
1.1e-03 |
KCNJ11 PMS2P5 RBL2 TCTA |
Illnesses of father: Heart disease |
1.54 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZCCHC24 |
Illnesses of siblings: Diabetes |
8.32 |
6 |
2 |
4.4 |
1.00 |
2.0e-05 |
EIF2S2P3 IGF2BP2 PMS2P5 RBM6 TCF7L2 WFS1 |
Smoking status: Previous |
1.47 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DAND5 |
Forced expiratory volume in 1-second (FEV1), predicted |
2.52 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
JAZF1 KCNJ11 |
Whole body fat-free mass |
3.71 |
7 |
4 |
8.9 |
0.48 |
2.8e-01 |
FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA |
Leg fat-free mass (right) |
3.19 |
4 |
3 |
6.7 |
0.32 |
6.8e-01 |
FNDC4 RBL2 RBM6 SNUPN |
Arm fat percentage (left) |
2.47 |
4 |
1 |
2.2 |
0.17 |
8.3e-01 |
PMS2P5 RBM6 TCF7L2 TCTA |
Mood swings |
2.03 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Long-standing illness, disability or infirmity |
3.61 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 PMS2P5 RBM6 |
Diabetes diagnosed by doctor |
29.87 |
19 |
17 |
37.8 |
1.00 |
3.0e-21 |
ANK1 DAND5 EIF2S2P3 FNDC4 IGF2BP2 JAZF1 KCNJ11 NOTCH2 PMS2P5 RBL2 RBM6 SMYD2 SNUPN SSR1 TCF7L2 TCTA UBE2E2 WFS1 ZCCHC24 |
Qualifications: nursing, teaching |
1.73 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 TCF7L2 |
Medication for cholesterol |
3.10 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 RBL2 |
Asthma (self-reported) |
1.83 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
EIF2S2P3 JAZF1 RBM6 |
Osteoporosis (self-reported) |
1.56 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 TCTA |
Medication: Aspirin |
2.82 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 |
Medication: Gliclazide |
11.37 |
7 |
2 |
4.4 |
0.99 |
9.3e-06 |
EIF2S2P3 IGF2BP2 JAZF1 KCNJ11 TCF7L2 UBE2E2 WFS1 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.52 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
IGF2BP2 JAZF1 |
Whole body water mass |
3.81 |
7 |
4 |
8.9 |
0.47 |
2.8e-01 |
FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA |
Leg predicted mass (right) |
3.19 |
4 |
3 |
6.7 |
0.32 |
6.8e-01 |
FNDC4 RBL2 RBM6 SNUPN |
Arm fat mass (left) |
2.97 |
5 |
2 |
4.4 |
0.35 |
5.6e-01 |
FNDC4 PMS2P5 RBM6 TCF7L2 TCTA |
Number of self-reported non-cancer illnesses |
4.00 |
5 |
2 |
4.4 |
0.50 |
3.9e-01 |
FNDC4 IGF2BP2 JAZF1 PMS2P5 RBM6 |
Miserableness |
1.72 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBM6 |
Mother's age at death |
1.91 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SNUPN |
Financial situation satisfaction |
1.90 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Medication: Blood pressure |
2.47 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
KCNJ11 PMS2P5 TCTA |
High cholesterol (Self-reported) |
5.97 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Medication: Atorvastatin |
4.76 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 TCF7L2 |
Basal metabolic rate |
3.65 |
8 |
3 |
6.7 |
0.33 |
4.3e-01 |
FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCF7L2 TCTA |
Leg fat percentage (left) |
3.96 |
7 |
3 |
6.7 |
0.35 |
4.4e-01 |
PMS2P5 RBL2 RBM6 SNUPN TCF7L2 TCTA ZCCHC24 |
Arm fat-free mass (left) |
4.01 |
7 |
2 |
4.4 |
0.57 |
1.8e-01 |
FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA |
Average weekly beer plus cider intake |
1.34 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Age started oral contraceptive pill |
1.88 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Diastolic blood pressure, automated reading |
2.18 |
4 |
2 |
4.4 |
0.38 |
6.2e-01 |
PMS2P5 RBM6 TCF7L2 TCTA |
Commuting to job workplace: Cycle |
1.97 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBL2 SNUPN |
Vascular/heart problems diagnosed by doctor |
2.61 |
5 |
1 |
2.2 |
-0.95 |
1.3e-02 |
IGF2BP2 KCNJ11 PMS2P5 RBL2 TCTA |
Cholesterol lowering medication |
5.29 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 TCF7L2 |
Pain experienced in last month |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Alcohol drinker status: Previous |
1.72 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DAND5 |
Pack years of smoking |
1.09 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PMS2P5 |
Impedance of whole body |
4.24 |
7 |
4 |
8.9 |
0.09 |
8.5e-01 |
FNDC4 JAZF1 KCNJ11 NOTCH2 PMS2P5 RBM6 TCF7L2 |
Leg fat mass (left) |
3.79 |
6 |
3 |
6.7 |
0.35 |
4.9e-01 |
FNDC4 PMS2P5 RBM6 TCF7L2 TCTA ZCCHC24 |
Arm predicted mass (left) |
4.06 |
7 |
2 |
4.4 |
0.56 |
1.9e-01 |
FNDC4 JAZF1 RBL2 RBM6 SNUPN SSR1 TCTA |